Johan Folkunger appointed new CEO of SpectraCure AB
The Board of Directors of SpectraCure has appointed Johan Folkunger new CEO, with a clear mandate to prepare and lead the Company into the next phase, commercialization. Johan Folkunger has held senior positions in a number of life science and medical technology companies, most recently as responsible for the Medical Technology business area at the […]
Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
Following the discussions at Investigator Meetings during November 2020 – February 2021, in which doctors and representatives of the clinics included in the company's clinical study participated, a status update follows in light of the current pandemic. Participating hospitals are University College London Hospital, Princess Margaret Cancer Centre in Toronto, University of Pennsylvania Hospital in […]
Positive discussions at SpectraCure’s Investigator Meeting
SpectraCure has held an Investigator Meeting where the topic of discussion was statistics and results from the treatments conducted in the Company's clinical study. The discussions at the meeting will also form the basis of the forthcoming application for Accelerated Approval. Physicians and representatives of the hospitals included in the study participated in the meeting: […]
Interim Report Q3, 2020
Third quarter 2020 Figures for 2020 and 2019 refer to the Group. Other operating income amounted to KSEK 1,656 (692) Result after taxes amounted to KSEK -2,348 (-3,054) Basic and diluted earnings per share: SEK -0.02 (-0.04) The cash flow from operating activities was KSEK -5,300 (-3,072 Nine months, Jan-Sep 2020 Figures for 2020 and […]
Interim Report Q2, 2020
Second quarter 2020 All figures for 2020 and 2019 refer to the Group.Other operating income amounted to kSEK 872 (663) Result after taxes amounted to kSEK -4,810 (-4,149) Basic and diluted earnings per share: SEK -0.05 (-0.05) The cash flow from operating activities was kSEK -5,775 (-3,547) First half of 2020 Other operating income […]
SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue
SpectraCure AB’s (publ) (Nasdaq First North Premier Growth Market: SPEC) (“SpectraCure” or the “Company”) fully guaranteed new Units issue with preferential rights for the Company’s existing shareholders (the “Rights Issue”), was fully subscribed. Through the Rights Issue, SpectraCure will receive proceeds amounting to approximately SEK 140 million before transaction costs. Not for publication, distribution or […]
Wider range of prospective patients in the UK, Canada and the US for continued clinical study
As previously disclosed, the US authority FDA has approved SpectraCure's new and revised study protocol for the clinical study on patients with recurrent prostate cancer. The protocol has also been approved by the UK and Canadian authorities. The new protocol expands the inclusion criteria for Gleason score, which allows a wider range of candidates to […]
A future alternative to hormonal treatment for prostate cancer
At this year's cancer congress in Chicago (ASCO), novel hormone treatments of patients suffering from non-metastatic castration-resistant prostate cancer were recognized. There are currently no efficient treatment options for the condition. Prostate cancer is the most common form of cancer in the western world. Every year, approximately 600,000 new cases are diagnosed in the US […]
Subscription period postponed for the rights issue. Other conditions remain unchanged
SpectraCure AB (publ) postpones the subscription period for the rights issue which was announced on 5 May 2020. The new subscription period is between Friday, 5 June 2020 and Tuesday, 23 June 2020 inclusive. All other terms and conditions of the rights issue remain unchanged. The Board of Directors of SpectraCure AB (publ) has resolved to postpone […]
Patent application submitted to protect new technology
SpectraCure has submitted a new patent application to the European Patent Office. The patent application regards the technical solution used in the new generation of SpectraCure's treatment system. The technology makes it possible to use the same optical fiber for both treatment and dose monitoring; together with the IDOSE software, this is what makes the […]
